ASCO GI 2021 | Trials in progress presented at ASCO GI 2021

Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, updates us on key trials in progress presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Firstly, Dr Wainberg discusses an ongoing Phase I trial in progress investigating the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in patients with HER2-positive tumors. MT-5111 is a novel HER2-targeting engineered toxin body that may overcome mechanisms of resistance to existing HER2 targeted therapies. Secondly, Dr Wainberg discusses an ongoing study in colorectal cancer evaluating tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification. Finally, the open-label, phase II study of patritumab deruxtecan, an antibody-drug conjugate inhibiting HER3 in patients with previously treated advanced/metastatic colorectal cancer is outlined. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).